31916 Federal Register / Vol. 65, No. 98 / Friday, May 19, 2000 / Notices

respondents to the FR 2910a would

reduce reporting burden by 3,690 hours.

Board of Governors of the Federal Reserve

System, May 15, 2000.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 00–12589 Filed 5–18–00; 8:45 am]

BILLING CODE 6210–01–P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and

Mergers of Bank Holding Companies

The companies listed in this notice

have applied to the Board for approval,

pursuant to the Bank Holding Company

Act of 1956 (12 U.S.C. 1841 et seq.)

(BHS Act), Regulation Y (12 CFR Part

225), and all other applicable statutes

and regulations to become a bank

holding company and/or to acquire the

assets or the ownership of, control of, or

the power to vote shares of a bank or

bank holding company and all of the

banks and nonbanking companies

owned by the bank holding company,

including the companies listed below.

The applications listed below, as well

as other related filings required by the

Board, are available for immediate

inspection at the Federal Reserve Bank

indicated. The application also will be

available for inspection at the offices of

the Board of Governors. Interested

persons may express their views in

writing on the standards enumerated in

the BHC Act (12 U.S.C. 1842(c)). If the

proposal also involves the acquisition of

a nonbanking company, the review also

includes whether the acquisition of the

nonbanking company complies with the

standards in section 4 of the BHC Act

(12 U.S.C. 1843). Unless otherwise

noted, nonbanking activities will be

conducted throughout the United States.

Additional information on all bank

holding companies may be obtained

from the National Information Center

website at www.ffiec.gov/nic/.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than June 12, 2000.

A. Federal Reserve Bank of Chicago

(Phillip Jackson, Applications Officer)

230 South LaSalle Street, Chicago,

Illinois 60690–1414:

1. Antioch Holding Company,

Antioch, Illinois; to acquire 24.99

percent of the voting shares of Lakes

Region Bancorp, Inc, Third Lake,

Illinois, and thereby indirectly acquire

Anchor Bank, Third Lake, Illinois.

B. Federal Reserve Bank of St. Louis

(Randall C. Sumner, Vice President) 411

Locust Street, St. Louis, Missouri

63166–2034;

1. Valley Capital Corporation,

Greenwood, Mississippi; to merge with

State Capital Corporation, Brookhaven,

Mississippi, and thereby indirectly

acquire State Bank and Trust Company,

Brookhaven, Mississippi.

Board of Governors of the Federal Reserve

System, May 15, 2000.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 00–12588 Filed 5–18–00; 8:45 am]

BILLING CODE 6210–01–P

BOARD OF GOVERNORS OF THE

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting; Notice

AGENCY HOLDING THE MEETING: Board of

Governors of the Federal Reserve

System.

TIME AND DATE: 10 a.m., Wednesday,

May 24, 2000.

PLACE: Marriner S. Eccles Federal

Reserve Board Building, 20th and C

Streets, NW., Washington, DC 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED: 

1. Personnel actions (appointments,

promotions, assignments,

reassignments, and salary actions)

involving individual Federal Reserve

System employees.

2. Any matters carried forward from a

previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION:

Lynn S. Fox, Assistant to the Board;

202–452–3204.

SUPPLEMENTARY INFORMATION: You may

call 202–452–3206 beginning at

approximately 5 p.m. two business days

before the meeting for a recorded

announcement of bank and bank

holding company applications

scheduled for the meeting; or you may

contact the Board’s Web site at http://

www.federalreserve.gov for an

electronic announcement that not only

lists applications, but also indicates

procedural and other information about

the meeting.

Dated: May 17, 2000.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 00–12744 Filed 5–17–00; 10:54 am]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 00D–1278]

Draft Guidance for Industry on Female

Sexual Dysfunction: Clinical

Development of Drug Products for

Treatment; Availability

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

availability of a draft guidance for

industry entitled ‘‘Female Sexual

Dysfunction: Clinical Development of

Drug Products for Treatment.’’ The draft

guidance is intended to provide

recommendations to industry on the

development of drug products for the

treatment of female sexual dysfunction

(FSD).

DATES: Submit written comments on the

draft guidance by July 18, 2000. General

comments on agency guidance

documents are welcome at any time.

ADDRESSES: Copies of this draft

guidance for industry can be obtained

on the Internet at http://www.fda.gov/

cder/guidance/index.htm. Submit

written requests for single copies of the

draft guidance to the Drug Information

Branch (HFD–210), Center for Drug

Evaluation and Research, Food and

Drug Administration, 5600 Fishers

Lane, Rockville, MD 20857. Send one

self-addressed adhesive label to assist

that office in processing your requests.

Submit written comments on the draft

guidance to the Dockets Management

Branch (HFA–305), Food and Drug

Administration, 5630 Fishers Lane, rm.

1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:

Lana L. Pauls, Center for Drug

Evaluation and Research (HFD–580),

Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–827–4260.

SUPPLEMENTARY INFORMATION: FDA is

announcing the availability of a draft

guidance for industry entitled ‘‘Female

Sexual Dysfunction: Clinical

Development of Drug Products for

Treatment.’’ The draft guidance

provides recommendations for sponsors

designing clinical trials in support of

new drug applications for the treatment

of FSD. It includes recommendations on

the appropriate definition of the patient

population to be studied, inclusion and

exclusion criteria, the use of scales and

questionnaires to assess FSD, and